Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
11:00am, Tuesday, 21'st Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
08:45am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQ: REGN). The laws
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
07:25am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reg
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Lawsuit - REGN
06:30am, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the feder
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the
NEW YORK , Jan. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wipin
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:15am, Monday, 20'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:55am, Monday, 20'th Jan 2025
LOS ANGELES , Jan. 20, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc.
